Clinical outcomes for patients with Gleason Score 10 prostate adenocarcinoma: results from a multi-institutional consortium study

Gleason 10 prostate cancer is extremely aggressive, and clinical outcomes are largely unknown due to its rarity. This study provides benchmark clinical outcomes information for patients with Gleason 10 prostate cancer with data extracted from a large multi-institutional database. Though it follows an aggressive course, the majority of patients are free from disease at 5 years, and there may be benefits to treating with radiation and brachytherapy.

https://ift.tt/2GEkqsC